# A Study for Non-Smoker Patients With Nonsquamous Non-Small Cell Lung Cancer

> **NCT00550173** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 247 (actual)

## Conditions studied

- Non-Small-Cell Lung Cancer

## Interventions

- **DRUG:** pemetrexed
- **DRUG:** erlotinib

## Key facts

- **NCT ID:** NCT00550173
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2012-01
- **Final completion:** 2012-01
- **Target enrollment:** 247 (ACTUAL)
- **Last updated:** 2013-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00550173

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00550173, "A Study for Non-Smoker Patients With Nonsquamous Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-09-23 from https://api.ai-analytics.org/clinical/NCT00550173. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*